Genfit S.A. (FRA:XUPB)

Germany flag Germany · Delayed Price · Currency is EUR
5.25
-0.45 (-7.89%)
Jan 27, 2026, 11:48 AM EST
59.09%
Market Cap278.85M +64.0%
Revenue (ttm)45.13M -43.9%
Net Income-38.76M
EPS-0.81
Shares Outn/a
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume18
Average Volume1
Open5.25
Previous Close5.70
Day's Range5.25 - 5.25
52-Week Range2.78 - 5.70
Betan/a
RSI60.48
Earnings DateApr 2, 2026

About Genfit

Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patien... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1999
Employees 188
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol XUPB
Full Company Profile

Financial Performance

Financial Statements